Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Conditions:   Advanced HER2 Negative Breast Carcinoma;   HRD+Breast Cancer Interventions:   Drug: fluzoparib+chidamide;   Drug: fluzoparib+camrelizumab Sponsor:   Tianjin Medical University Cancer Institute and Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials